Esmolol Hydrochloride

• CAT Number: A000886
• CAS Number: 81161-17-3
• Molecular Formula: C16H26ClNO4
• Molecular Weight: 331.8
• Purity: ≥95%
• Target: Beta Adrenergic Antagonist
• Storage: -20°C
• InChI: 1S/C16H25NO4.ClH/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3;/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3;1H
• InChIKey: GEKNCWBANDDJJL-UHFFFAOYSA-N
• SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl

Esmolol Hydrochloride is the hydrochloride salt form of esmolol, a short and rapid-acting beta adrenergic antagonist belonging to the class II anti-arrhythmic drugs and devoid of intrinsic sympathomimetic activity. Esmolol hydrochloride competitively blocks beta-1 adrenergic receptors in cardiac muscle and reduces the contractility and cardiac rate of heart muscle, thereby decreasing cardiac output and myocardial oxygen demands. This agent also decreases sympathetic output centrally and blocks renin secretion. At higher doses, esmolol hydrochloride also blocks beta-2 receptors located in bronchial and vascular smooth muscle, thereby leading to smooth muscle relaxation.

Reference

1: Zhao B, Sun W. Incompatibility of esmolol hydrochloride and furosemide in a
central venous access port. Am J Health Syst Pharm. 2014 Jun 1;71(11):901-2. doi:
10.2146/ajhp130526. PubMed PMID: 24830993.

2: Wiest DB, Garner SS, Childress LM. Stability of esmolol hydrochloride in 5%
dextrose injection. Am J Health Syst Pharm. 1995 Apr 1;52(7):716-8. PubMed PMID:
7627740.

3: Baaske DM, Dykstra SD, Wagenknecht DM, Karnatz NN. Stability of esmolol
hydrochloride in intravenous solutions. Am J Hosp Pharm. 1994 Nov
1;51(21):2693-6. PubMed PMID: 7856582.

4: Jordan D, Shulman SM, Miller ED Jr. Esmolol hydrochloride, sodium
nitroprusside, and isoflurane differ in their ability to alter peripheral
sympathetic responses. Anesth Analg. 1993 Aug;77(2):281-90. PubMed PMID: 8102224.

5: Vucevic M, Purdy GM, Ellis FR. Esmolol hydrochloride for management of the
cardiovascular stress responses to laryngoscopy and tracheal intubation. Br J
Anaesth. 1992 May;68(5):529-30. PubMed PMID: 1642945.

6: Schaaf LJ, Robinson DH, Vogel GJ, Wulf BG, Drda KD, Moses JO. Stability of
esmolol hydrochloride in the presence of aminophylline, bretylium tosylate,
heparin sodium, and procainamide hydrochloride. Am J Hosp Pharm. 1990
Jul;47(7):1567-71. PubMed PMID: 2368749.

7: Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE.
Stability of esmolol hydrochloride and sodium nitroprusside in intravenous
admixtures. Am J Hosp Pharm. 1989 Jan;46(1):101-4. PubMed PMID: 2565685.

8: Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol
hydrochloride and various injectable drugs during simulated Y-site injection. Am
J Hosp Pharm. 1988 Mar;45(3):630-2. Erratum in: Am J Hosp Pharm 1988
Jun;45(6):1281. PubMed PMID: 2897164.

9: Karnatz NN, Wong J, Kesler H, Baaske DM, Speicher ER. Compatibility of esmolol
hydrochloride with morphine sulfate and fentanyl citrate during simulated Y-site
administration. Am J Hosp Pharm. 1988 Feb;45(2):368-71. PubMed PMID: 2896460.

10: Thompson DF, Thompson GD. Visual compatibility of esmolol hydrochloride and
furosemide in 5% dextrose or 0.9% sodium chloride injections. Am J Hosp Pharm.
1987 Dec;44(12):2740. PubMed PMID: 3434585.